FDA Grants Fast Track to PVX108 Peanut Peptide ImmunotherapyPVX108 received FDA Fast Track designation in August 2026 as a synthetic T-cell epitope peptide therapy for peanut allergy—one of the first allergen immunotherapy programs built entirely on short peptides rather than whole extracts.
